奥替库单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | oxLDL |
| 臨床資料 | |
| 其他名稱 | 奥替苏单抗、BI-204、MLDL1278A |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1314241-10-5 |
| ChemSpider |
|
| UNII | |
奥替库单抗（INN：Orticumab；开发代号：BI-204、MLDL1278A），或译奥替苏单抗，是一种人单克隆抗体，用作抗炎剂并与oxLDL结合。它充当免疫调节剂。[1]该药物可以用来治疗动脉粥样硬化。[2]该药物由BioInvent公司研究开发。[3]
参考资料
[编辑]- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-21]. （原始内容存档 (PDF)于2016-03-04）.
- ^ Yao Mattisson, Ingrid; Rattik, Sara; Björkbacka, Harry; Ljungcrantz, Irena; Terrinoni, Manuela; Lebens, Michael; Holmgren, Jan; Fredrikson, Gunilla Nordin; Gullstrand, Birgitta; Bengtsson, Anders A.; Nilsson, Jan. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascular Pharmacology. 2021-10-01, 140 [2024-01-21]. ISSN 1537-1891. doi:10.1016/j.vph.2021.106863. （原始内容存档于2024-07-16）.
- ^ Recruitment of patients completed in phase II study with BI-204. BioInvent. 2012-03-02 [2024-01-21] （英语）.